Why Compare These Two Leading Weight Management Treatments?
Which Is Better Wegovy or Mounjaro: Understanding the Key Differences
When evaluating which is better Wegovy or Mounjaro, the fundamental distinction lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone to promote satiety and reduce appetite. Mounjaro, containing tirzepatide, takes a dual approach by targeting both GIP and GLP-1 receptors, potentially offering a more comprehensive hormonal response. Both are prescription-only medicines that require clinical assessment and ongoing medical supervision.
The dosing schedules also differ significantly between these treatments. Wegovy follows a five-step escalation from 0.25mg to the maintenance dose of 2.4mg over 16 weeks, whilst Mounjaro offers six dose levels ranging from 2.5mg to 15mg. Your prescriber will determine which is better Wegovy or Mounjaro based on your individual response, tolerance, and weight management goals. At EverydayMeds, both treatments are available through the same streamlined process with professional clinical oversight.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
Understanding the financial commitment helps determine which is better Wegovy or Mounjaro for your budget. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles offer convenience, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, whilst the Ultimate Stability Trio provides three months of maintenance supply at 2.4mg for £649.99. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25.
Mounjaro pricing follows a different structure reflecting its alternative dosing schedule and mechanism. When comparing which is better Wegovy or Mounjaro financially, consider not just the individual pen costs but also the total treatment duration and your likely maintenance dose. Both treatments require long-term commitment for sustained results, as clinical studies demonstrate that discontinuation typically leads to weight regain. Our bundle options for both medications help ensure treatment continuity whilst managing costs effectively.
Clinical Evidence: Wegovy vs Mounjaro Trial Results
Clinical trials provide objective data when considering which is better Wegovy or Mounjaro. In the STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved an average weight reduction of approximately 15% at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent efficacy across different patient populations, including those with type 2 diabetes and those receiving intensive behavioural therapy support.
Mounjaro's SURMOUNT trials showed its own impressive results, though direct comparison between trial outcomes isn't appropriate due to different study designs, populations, and endpoints. Both treatments have demonstrated significant cardiovascular benefits in dedicated outcome studies. When determining which is better Wegovy or Mounjaro, your prescriber will consider your individual medical history, existing conditions, and treatment goals rather than relying solely on population-level trial data.
How Wegovy Works in Weight Management
Understanding Wegovy's mechanism helps clarify when it might be the preferred choice in the Wegovy vs Mounjaro comparison. As a GLP-1 receptor agonist, semaglutide mimics the action of glucagon-like peptide-1, a hormone naturally released by your intestines after eating. This hormone signals to your brain that you're full, reducing appetite and promoting satiety after smaller meals. The medication may also slow gastric emptying, helping you feel satisfied for longer periods. Additionally, Wegovy can reduce food cravings by acting on appetite centres in the brain, particularly areas associated with reward-driven eating behaviours. This comprehensive approach to appetite regulation makes Wegovy effective when combined with lifestyle modifications including reduced-calorie diet and increased physical activity.
EverydayMeds Ordering Process for Both Treatments
Whether you're leaning toward Wegovy or Mounjaro in your comparison, EverydayMeds offers the same streamlined process for both treatments. Begin with our 3-minute online clinical assessment, providing details about your medical history, current medications, and weight management goals. Our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), determining which treatment is most appropriate for your circumstances. Once approved, your medication is dispatched via next-day delivery using temperature-controlled cold-chain packaging to maintain efficacy. This process ensures both treatments meet the same high standards of clinical oversight and pharmaceutical care through our GPhC-registered pharmacy (#9012878). Our team remains available throughout your treatment journey to address any questions about administration, side effects, or treatment progression.
Storage and Practical Considerations
Practical factors often influence the decision of which is better Wegovy or Mounjaro for your lifestyle. Wegovy requires refrigeration at 2-8°C before first use but can remain at room temperature below 30°C for up to 6 weeks once removed from the fridge, making it superior for travel compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen design offers intuitive dose administration with clear visual confirmation of successful injection. Wegovy's dose escalation schedule is mandatory and cannot be skipped, requiring commitment to the 16-week titration period before reaching maintenance dosing. Both treatments require once-weekly injection, typically administered on the same day each week. Your prescriber will provide comprehensive guidance on injection technique, rotation of injection sites, and proper disposal of used pens through our clinical support programme.
Individual Response Patterns: Personalising Your Choice
The question of which is better Wegovy or Mounjaro ultimately depends on your individual response pattern and tolerability profile. Some patients respond more favourably to Wegovy's single-hormone approach, whilst others benefit from Mounjaro's dual-receptor mechanism. Factors such as existing diabetes status, cardiovascular risk profile, and previous weight management attempts all influence treatment selection. Your prescriber considers these variables alongside practical preferences like storage requirements and dosing convenience.
Genetic factors, metabolic rate, and existing gut hormone sensitivity can affect how well you respond to either treatment. Some patients experience optimal results with Wegovy's established semaglutide formulation, whilst others find Mounjaro's tirzepatide more effective for their specific physiology. The beauty of accessing both treatments through EverydayMeds means your prescriber can switch between options if your initial choice doesn't deliver expected results, ensuring you receive the most effective treatment for your circumstances.
Making Your Decision: Next Steps with EverydayMeds
Rather than definitively answering which is better Wegovy or Mounjaro, the focus should be on which is better for you specifically. Both treatments are available through EverydayMeds with identical clinical standards, delivery options, and ongoing support. Complete our clinical assessment to discuss your preferences with a qualified prescriber who can guide your decision based on medical evidence and individual factors. New customers benefit from code FIRST40, whilst returning customers use DOSE25, both applied at checkout to reach our competitive pricing. Your journey toward effective weight management begins with professional guidance, whether that leads to Wegovy, Mounjaro, or potentially transitioning between treatments as your needs evolve. Contact our clinical team today through https://everydaymeds.co.uk/collections/weight-loss to start your personalised consultation and receive expert recommendation on the most suitable treatment option.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
